12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Deals

OraSure, Thermo Fisher, Roche deal

OraSure terminated a 2006 deal with Roche to develop oral fluid assays to detect commonly abused drugs. Under the deal, OraSure and Roche had developed and received 510(k) clearance from FDA for assays to detect phencyclidine (PCP), opiates, cocaine and methamphetamines/amphetamines. Roche will make an $8.3 million payment, provide transitional product support services and supply the assays for up to...

Read the full 276 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >